Absence of mutations in the coding sequence of the potential tumor suppessor 3pK in metastatic melanoma

Journal of Carcinogenesis

Volumn 4, Issue , 2005, Pages

  Houben, Roland ^b   Becker, Jüergen C ^b   Rapp, Ulf R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHROMOSOME 3P KINASE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME 3P; DNA FLANKING REGION; EXON; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; INTRON; MELANOMA; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; ONCOGENE N RAS; PHENOTYPE; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

EID: 29944445374     PISSN: 14773163     EISSN: 14773163     Source Type: Journal    
DOI: 10.1186/1477-3163-4-23     Document Type: Article

References (19)

1. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002, 1602: 151-161.
2. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397: 164-168.
3. Bea S, Tort F, Pinyol M et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001, 61: 2409-2412.
4. Vonlanthen S, Heighway J, Altermatt HJ et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001, 84: 1372-1376.
5. van Kemenade FJ, Raaphorst FM, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97: 3996-3901.
6. Itahana K, Zou Y, Itahana Y et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003, 23: 389-401.
7. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423: 255-260.
8. Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423: 302-305.
9. Molofsky AV, Pardal R. Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425: 962-967.
10. Sithanandam G, Latif F, Duh FM et al. 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol 1996, 16: 868-876.
11. Voncken JW, Niessen H, Neufeld B et al. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J Biol Chem 2005, 280: 5178-5187.
12. Ludwig S. Engel K. Hoffmeyer A et al. 3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol 1996, 16: 6687-6697.
13. Nottage M, Siu LL. Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr Pharm Des 2002, 8: 2231-2242.
14. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 2002, 3: 709-718.
15. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003, 1653: 25-40.
16. Kerkhoff E, Rapp UR. High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res 1998, 58: 1636-1640.
17. Houben R, Becker JC, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004, 3: 6.
18. van der Velden PA, Metzelaar-Blok JA, Bergman W et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 2001, 61: 5303-5306.
19. Protopopov AI, Li J, Winberg G et al. Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. J Gene Med 2002, 4: 397-406.